Q-omics provides the consensus-scored THYN1 profile across patient tissues and cancer cell-line models. THYN1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, THYN1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, THYN1 protein abundance shows 22,576 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, and GBM as cancer lineages where THYN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THYN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THYN1 survival associations across molecular data types. THYN1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THYN1 RNA expression–survival associations across cancer types. High THYN1 expression shows unfavorable associations in KICH, ACC and UVM, but favorable associations in LUAD, THCA and LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for THYN1 RNA expression.
This table summarizes THYN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for THYN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THYN1 shows lower tumor expression in KICH and BRCA and higher tumor expression in THCA, LUAD, LIHC and COAD. The KICH box plot shows higher THYN1 RNA expression in normal versus tumor tissue (log2 FC = −1.134, t-test p < 0.001).
This table shows molecular features associated with THYN1 in patient tissues and cancer cell lines. In patient samples, THYN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, THYN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
